7B)

7B). == FIG 7. cytokines, and chemokines. After immunization of C57BL/6 mice with a homologous protocol (MVA-CHIKV/MVA-CHIKV), strong, broad, polyfunctional, and durable CHIKV-specific CD8+T cell responses were elicited. The CHIKV-specific CD8+T cells were preferentially directed against E1 and E2 proteins and, to a lesser extent, against C protein. CHIKV-specific CD8+memory T cells of a mainly effector memory phenotype were also induced. The humoral arm of the immune system was significantly induced, as MVA-CHIKV elicited high titers of neutralizing antibodies against CHIKV. Remarkably, a single dose of MVA-CHIKV guarded all mice after a high-dose challenge with CHIKV. In summary, MVA-CHIKV is an effective vaccine against chikungunya computer virus contamination that induced strong, broad, highly polyfunctional, and long-lasting CHIKV-specific CD8+T cell responses, together with neutralizing antibodies against CHIKV. These results support the concern of MVA-CHIKV as a potential vaccine candidate against CHIKV. IMPORTANCEWe have developed a novel vaccine candidate against chikungunya PF-06256142 computer virus (CHIKV) based on the highly attenuated poxvirus vector altered vaccinia computer virus Ankara (MVA) expressing the CHIKV C, E3, E2, 6K, and E1 structural genes (termed MVA-CHIKV). Our findings revealed that MVA-CHIKV is usually a highly effective vaccine against chikungunya computer virus, with a single dose of the vaccine protecting all mice after a high-dose challenge with CHIKV. Furthermore, MVA-CHIKV is highly immunogenic, inducing strong innate responses: high, broad, polyfunctional, and long-lasting CHIKV-specific CD8+T cell responses, together with neutralizing antibodies against CHIKV. This work provides PF-06256142 a potential vaccine candidate against CHIKV. == INTRODUCTION == Chikungunya computer virus (CHIKV) is an alphavirus of the familyTogaviridaethat is usually transmitted by mosquitoes of the genusAedes(1). The computer virus causes chikungunya fever in humans, a disease characterized by skin rash, high fever, PF-06256142 headache, vomiting, myalgia, and, mainly, polyarthralgia (16). Most of the symptoms resolve after 10 days, but the polyarthralgia can persist for months or years (4,6,7), and severe symptoms, such as encephalitis, hemorrhagic disease, and mortality, have also been described (5,8,9). CHIKV contains a positive, single-stranded RNA genome of around 11.8 kb which encodes four nonstructural and five structural proteins (10,11). The nonstructural proteins (nsP1, nsP2, nsP3, and nsP4) are required for computer virus replication. The structural proteins are cleaved by capsid (C) autoproteinase and signalases from a polyprotein precursor to generate the C and envelope (E3, E2, 6K, and E1) proteins (1012). Virions are 70-nm enveloped particles made up of 240 heterodimers of E1/E2 glycoproteins on their surfaces (13). CHIKV contamination was Rabbit Polyclonal to MN1 first described in 1952 in Tanzania, and the computer virus was isolated in 1953 (14). In 2005, CHIKV reemerged as an outbreak on La Runion Island (15) and has spread to different places in Africa, islands in the Indian Ocean, India, Southeast Asia, and southern Europe, affecting millions of people PF-06256142 (3,1623), revealing that the computer virus is usually a public threat that could cause a worldwide epidemic (4,6,24,25). Thus, the development of a prophylactic CHIKV vaccine is usually a high priority that PF-06256142 has been moving forward to control CHIKV infection (26). Several vaccine approaches against CHIKV, such as a formalin-inactivated CHIKV (2729), a live attenuated CHIKV (30,31), a recombinant E2 protein-based vaccine (32), chimeric alphavirus vectors (3335), an adenovirus vector (36), a virus-like particle vaccine (3739), DNA vaccines (40,41), an internal ribosome entry site (IRES)-based live attenuated CHIKV vaccine (4244), and a recombinant measles vaccine (45), have been developed. However, currently there are no licensed CHIKV vaccines or effective antiviral therapies that could control the disease (26). Modified vaccinia virus Ankara (MVA) is a highly attenuated poxvirus strain that has been widely used in several preclinical and clinical trials as a vaccine vector against many infectious diseases and cancer (4649), showing that MVA vectors are safe, express high levels of heterologous antigens, and are strongly immunogenic. Thus, the use of MVA as a vector to generate a vaccine candidate against CHIKV could.